Leerink Partners Cuts Price Target on Aegerion Pharma (AEGR) Following 1Q Miss and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
After-Hours Stock Movers 05/16: (GSAT) (CYH) (A) Higher; (AEGR) (RLYP) (P) Lower (more...)
May 16, 2016 6:19 PM EDTToday's After-Hours Movers:
Aegerion Pharma (NASDAQ: AEGR) 13.4% LOWER; reported Q1 EPS of ($1.72), $1.14 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $35.7 million versus the consensus estimate of $43 million. Aegerion recorded $26.2 million in net product sales of JUXTAPID® (lomitapide) capsules in the first quarter of 2016, $23.6 million, or 90%, of which was from prescriptions written in the United... More
Aegerion Pharma (AEGR) Misses Q1 EPS Views; Trims FY16 Outlook
May 16, 2016 4:09 PM EDTAegerion Pharma (NASDAQ: AEGR) reported Q1 EPS of ($1.72), $1.14 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $35.7 million versus the consensus estimate of $43 million.
Aegerion recorded $26.2 million in net product sales of JUXTAPID® (lomitapide) capsules in the first quarter of... More
